Diagnostic and prognostic value of microRNA-2355-3p and contribution to the progression in lung adenocarcinoma

References

• Skřičková J, Kadlec B, Venclíček O, et al. Lung cancer. Cas Lek Cesk. 2018;157(5):226–236.
   PubMedGoogle Scholar
• Cao M, Li H, Sun D, et al. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond). 2020;40(5):205–210.
   PubMed Web of Science ®Google Scholar
• Woodard GA, Jones KD, Jablons DM. Lung Cancer Staging and Prognosis. Cancer Treat Res. 2016;170:47–75.
   PubMedGoogle Scholar
• Warth A, Muley T, Meister M, et al. The novel histologic international association for the study of lung cancer/American thoracic society/European respiratory society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J clin oncol. 2012;30(13):1438–1446.
   PubMed Web of Science ®Google Scholar
• Nasim F, Sabath BF, Eapen GA. Lung cancer. Med Clin North Am. 2019;103(3):463–473.
   PubMed Web of Science ®Google Scholar
• O’Dowd EL, Baldwin DR. Lung cancer screening-low dose CT for lung cancer screening: recent trial results and next steps. Br J Radiol. 2018;91(1090):20170460.
   PubMed Web of Science ®Google Scholar
• Bradley SH, Abraham S, Callister ME, et al. Sensitivity of chest X-ray for detecting lung cancer in people presenting with symptoms: a systematic review. Br J Gen Pract. 2019;69(689):e827–e835.
   PubMed Web of Science ®Google Scholar
• Hristova VA, Chan DW. Cancer biomarker discovery and translation: proteomics and beyond. Expert Rev Proteomics. 2019;16(2):93–103.
   PubMed Web of Science ®Google Scholar
• Kamps R, Brandão RD, Bosch BJ, et al. Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 2017;18(2). DOI:10.3390/ijms18020308
   PubMed Web of Science ®Google Scholar
• Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35(1):3–11.
   PubMed Web of Science ®Google Scholar
• Chu GCW, Lazare K, Sullivan F. Serum and blood based biomarkers for lung cancer screening: a systematic review. BMC Cancer. 2018;18(1):181.
   PubMedGoogle Scholar
• Sun Y, Chen G, He J, et al. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer. Bioengineered. 2021;12(1):325–340.
   PubMed Web of Science ®Google Scholar
• Zeybek A, Öz N, Kalemci S, et al. Diagnostic value of MiR-125b as a potential biomarker for stage I lung adenocarcinoma. Curr Mol Med. 2019;19(3):216–227.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wei J, Zhang W, et al. Serum exosomal miR-1290 is a potential biomarker for lung adenocarcinoma. Onco Targets Ther. 2020;13:7809–7818.
   PubMed Web of Science ®Google Scholar
• Chen L, Li Y, Lu J. Identification of circulating miR-762 as a novel diagnostic and prognostic biomarker for non-small cell lung cancer. Technol Cancer Res Treat. 2020;19:1533033820964222.
   Web of Science ®Google Scholar
• Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(5):568–577.
   PubMed Web of Science ®Google Scholar
• Liu B, Li X, Li C, et al. miR-25 mediates metastasis and epithelial-mesenchymal-transition in human esophageal squamous cell carcinoma via regulation of E-cadherin signaling. Bioengineered. 2019;10(1):679–688.
   PubMed Web of Science ®Google Scholar
• Zheng G, Huang J, Chen W, et al. circUBAP2 exacerbates malignant capabilities of NSCLC by targeting KLF4 through miR-3182 modulation. Aging (Albany NY). 2021;13(8):11083–11095.
   PubMedGoogle Scholar
• Luan T, Zhang TY, Lv ZH, et al. The lncRNA ALMS1-IT1 may promote malignant progression of lung adenocarcinoma via AVL9-mediated activation of the cyclin-dependent kinase pathway. FEBS Open Bio. 2021;11(5):1504–1515.
   PubMed Web of Science ®Google Scholar
• Liang Z, Xu J, Ma Z, et al. MiR-187 suppresses non-small-cell lung cancer cell proliferation by targeting FGF9. Bioengineered. 2020;11(1):70–80.
   PubMed Web of Science ®Google Scholar
• Balatti V, Croce CM. MicroRNA dysregulation and multi-targeted therapy for cancer treatment. Adv Biol Regul. 2020;75:100669.
   PubMedGoogle Scholar
• Yu T, Wang XY, Gong RG, et al. The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res. 2009;28(1):64.
   PubMedGoogle Scholar
• Hu Z, Wang X, Yang Y, et al. MicroRNA expression profiling of lung adenocarcinoma in Xuanwei, China: a preliminary study. Medicine (Baltimore). 2019;98(21):e15717.
   PubMed Web of Science ®Google Scholar
• Fekete JT, Welker Á, Győrffy B. miRNA expression signatures of therapy response in squamous cell carcinomas. Cancers (Basel). 2020;13(1). DOI:10.3390/cancers13010063
   PubMed Web of Science ®Google Scholar
• Liang Y, Wang B, Huang H, et al. Silenced SOX2-OT alleviates ventricular arrhythmia associated with heart failure by inhibiting NLRP3 expression via regulating miR-2355-3p. Immun Inflamm Dis. 2021;9(1):255–264.
   PubMed Web of Science ®Google Scholar
• Villalobos P, Wistuba II. Lung cancer biomarkers. Hematol Oncol Clin North Am. 2017;31(1):13–29.
   PubMed Web of Science ®Google Scholar
• Seijo LM, Peled N, Ajona D, et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J Thorac Oncol. 2019;14(3):343–357.
   PubMed Web of Science ®Google Scholar
• Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J clin oncol. 2014;32(8):768–773.
   PubMed Web of Science ®Google Scholar
• Ren ZP, Hou XB, Tian XD, et al. Identification of nine microRNAs as potential biomarkers for lung adenocarcinoma. FEBS Open Bio. 2019;9(2):315–327.
   PubMed Web of Science ®Google Scholar
• Feng M, Zhao J, Wang L, et al. Upregulated expression of serum exosomal microRNAs as diagnostic biomarkers of lung adenocarcinoma. Ann Clin Lab Sci. 2018;48(6):712–718.
   PubMed Web of Science ®Google Scholar
• Xia Y, Zhu Y, Zhou X, et al. Low expression of let-7 predicts poor prognosis in patients with multiple cancers: a meta-analysis. Tumour Biol. 2014;35(6):5143–5148.
   PubMedGoogle Scholar
• Kim Y, Kim H, Bang S, et al. MicroRNA-130b functions as an oncogene and is a predictive marker of poor prognosis in lung adenocarcinoma. Lab Invest. 2021;101(2):155–164.
   PubMed Web of Science ®Google Scholar
• Kim JS, Chun SH, Park S, et al. Identification of novel microRNA prognostic markers using cascaded Wx, a neural network-based framework, in lung adenocarcinoma patients. Cancers (Basel). 2020;12:7.
   Web of Science ®Google Scholar
• Wei L, Cuicui Z, Jing W, et al. Antiangiogenic drugs enhance the ability of invasion and metastasis of breast cancer cells under serum starvation and hypoxia. Zhonghua zhong liu za zhi [Chin J Oncol]. 2015;37(4):244–250.
   PubMedGoogle Scholar
• Zhang Q, Guan F, Fan T, et al. LncRNA WDFY3-AS2 suppresses proliferation and invasion in oesophageal squamous cell carcinoma by regulating miR-2355-5p/SOCS2 axis. J Cell Mol Med. 2020;24(14):8206–8220.
   PubMed Web of Science ®Google Scholar
• Gao F, Wu H, Wang R, et al. MicroRNA-485-5p suppresses the proliferation, migration and invasion of small cell lung cancer cells by targeting flotillin-2. Bioengineered. 2019;10(1):1–12.
   PubMed Web of Science ®Google Scholar